Tumor regression by anti-CD40 and interleukin-2: Role of CD40 in hematopoietic cells and organ-specific effects

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 8, 2004, Pages 534-539

  Welniak, Lisbeth A ^a   Shorts, Lynnette ^b   Subleski, Jeff ^b   Blazar, Bruce R ^c   Wiltrout, Robert H ^b   Murphy, William J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone marrow chimera; CD8+ T cell; Dendritic cell

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CULTURE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG TARGETING; ENDOTHELIUM CELL; HEMATOPOIETIC CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LIVER CELL; LIVER METASTASIS; LUNG METASTASIS; LYMPHOID ORGAN; MEDICAL ASSESSMENT; METASTASIS POTENTIAL; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; RECIPIENT; SPLEEN CELL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR REGRESSION; UNINEPHRECTOMY; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; BONE MARROW TRANSPLANTATION; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; IMMUNOPHENOTYPING; INTERLEUKIN-2; LIVER; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; SPLEEN; SURVIVAL RATE;

EID: 3543122350     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.05.006     Document Type: Article

References (18)

1. Clark L.B. Foy T.M. Noelle R.J. CD40 and its ligand Adv Immunol. 63 1996 43-78
2. Grewal I.S. Flavell R.A. A central role of CD40 ligand in the regulation of CD4+ T-cell responses Immunol Today 17 1996 410-414
3. van Kooten C. Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells Curr Opin Immunol. 9 1997 330-337
4. Caux C. Massacrier C. Vanbervliet B. et al. Activation of human dendritic cells through CD40 cross-linking J Exp Med. 180 1994 1263-1272
5. Ribas A. Butterfield L.H. Amarnani S.N. et al. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells Cancer Res. 61 2001 8787-8793
6. Murphy W.J. Welniak L. Back T. et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses J Immunol. 170 2003 2727-2733
7. Wigginton J.M. Komschlies K.L. Back T.C. Franco J.L. Brunda M.J. Wiltrout R.H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma J Natl Cancer Inst. 88 1996 38-43
8. Buhlmann J.E. Gonzalez M. Ginther B. et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease J Immunol. 162 1999 4373-4376
9. Fogler W.E. Volker K. Watanabe M. et al. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas J Immunol. 161 1998 6014-6021
10. Stamenkovic I. Clark E.A. Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas EMBO J. 8 1989 1403-1410
11. Funakoshi S. Longo D.L. Beckwith M. et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation Blood 83 1994 2787-2794
12. Hirano A. Longo D.L. Taub D.D. et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand Blood 93 1999 2999-3007
13. Szocinski J.L. Khaled A.R. Hixon J. et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax Blood 100 2002 217-223
14. Fyfe G.A. Fisher R.I. Rosenberg S.A. Sznol M. Parkinson D.R. Louie A.C. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy J Clin Oncol. 14 1996 2410-2411
15. Rosenberg S.A. Mule J.J. Spiess P.J. Reichert C.M. Schwarz S.L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 J Exp Med. 161 1985 1169-1188
16. Yang J.C. Schwarz S.L. Perry-Lalley D.M. Rosenberg S.A. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer Lymphokine Cytokine Res. 10 1991 475-480
17. Eisenthal A. Rosenberg S.A. Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2 Cancer Res. 49 1989 6953-6959
18. Donohue J.H. Rosenstein M. Chang A.E. Lotze M.T. Robb R.J. Rosenberg S.A. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma J Immunol. 132 1984 2123-2128